 The investigators preliminary results from the first pilot study have shown that cognition in Tysabri treated MS patients for two or more years, as measured by the SDMT or Cogstate battery is maintained, including the ability to learn. The investigators final data will be presented at the American Academy of Neurology AAN in 2015. 